Vivo Ventures: About Us

About Vivo

Investment Strategy

At Vivo Ventures, we leverage our internal expertise in evaluating data to generate outsized returns for company founders and employees as well as for our investors. The majority of Vivo's investments are in U.S. based companies with therapeutic products in clinical development.

In making investments we emphasize the following criteria:

The quality of the company's underlying technology, including supporting preclinical and clinical data
The market potential of the company's products
The strength of the company's intellectual property
The strength of the company's management team

Despite its focus on companies with later-stage products, Vivo is willing to work with companies (and their founders) that may not have significant infrastructure. We invest in companies with promising products at all financing stages (Series A to public companies), and work closely with founders and management to complete the development and commercial launch of those products and achieve a successful exit

Adding Value: Portfolio Synergy, Strategic Partnering and Technology Transfer

After an investment is made, Vivo works closely with the founders and management to build value.

We work to ensure the clinical development program is optimized in terms of disease indication, protocol design and regulatory strategy.
Intellectual property (IP) is another key component, and Vivo frequently becomes involved in helping guide the IP strategies of its portfolio companies.
The final step of Vivo's company-building is to develop a financing strategy with management to ensure the company's sustainability.

The portfolio of Vivo Ventures encompasses companies in a wide range of therapeutic areas and stages of development with products ranging from early clinical development to commercial stage. Because the strengths of one portfolio company are often complementary or synergistic with those of another, we encourage communication and potential collaboration among our companies whenever such collaboration makes business sense.